(MENAFN- Investor Brand Network) Lexaria began its human clinical study on oral nicotine alternatives, evaluating the effectiveness of its DehydraTECH-nicotine pouch performance
Earlier in the year, the company also announced the commencement of its HYPER-H21-4 human clinical study on the effectiveness of DehydraTECH-processed CBD for hypertension treatment Lexaria has also made some significant progress in the use of its technology for the enhanced delivery of antiviral drugs It hopes that before the end of 2022, it will have built sufficient data to effect meaningful industry progress and sustainable increases in valuation
lexaria bioscience (nasdaq: lexx) , since its inception, has been pushing the boundaries of drug delivery. Through its patented technology, DehydraTECH(TM), the company has achieved more efficient delivery of active pharmaceutical ingredients into the bloodstream while also increasing their bioavailability.
Its technology has seen application in pharmaceuticals, nutraceuticals, consumer packaged goods, and over-the-counter capsules, pills, tablets, and oral suspensions. Lexaria has explored its usage in the…
read more>>
NOTE TO INVESTORS:
The latest news and updates relating to LEXX are available in the company's newsroom at
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing
cbdnewsbreaks
crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published:
Do you have questions or are you interested in working with CNW?
ask our editor
CBDWire (CBDW)
Denver, Colorado
303.498.7722 Office
CBDWire is part of the
investorbrandnetwork .
MENAFN25112022000224011066ID1105231857
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.